Edition:
United States

Otonomy Inc (OTIC.OQ)

OTIC.OQ on NASDAQ Stock Exchange Global Select Market

4.20USD
4:00pm EDT
Change (% chg)

$0.15 (+3.70%)
Prev Close
$4.05
Open
$4.05
Day's High
$4.30
Day's Low
$4.05
Volume
2,521,094
Avg. Vol
50,332
52-wk High
$21.15
52-wk Low
$2.80

Chart for

About

Otonomy, Inc. is a biopharmaceutical company. The Company focuses on the development and commercialization of therapeutics for diseases and disorders of the ear. The Company's product candidates include OTIPRIO, OTO-104 and OTO-311. OTIPRIO is a single-dose, physician-administered antibacterial, which is used for the treatment... (more)

Overall

Beta: 3.15
Market Cap(Mil.): $133.01
Shares Outstanding(Mil.): 30.58
Dividend: --
Yield (%): --

Financials

  OTIC.OQ Industry Sector
P/E (TTM): -- 244.60 33.54
EPS (TTM): -2.45 -- --
ROI: -52.78 -5.33 13.09
ROE: -53.59 -6.88 15.10

BRIEF-Otonomy Qtrly Loss Per Share $0.37

* OTONOMY REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

May 09 2018

BRIEF-Otonomy Qtrly Loss Per Share $‍0.62​

* OTONOMY REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

Mar 08 2018

BRIEF-Otonomy Announces FDA Approval Of Otiprio For Acute Otitis Externa

* OTONOMY ANNOUNCES FDA APPROVAL OF OTIPRIO(R) FOR ACUTE OTITIS EXTERNA

Mar 02 2018

BRIEF-Otonomy Sees 2017 Non-Gaap Expenses Totaling $73-$78 Million

* OTONOMY INC - EXPECTS GAAP OPERATING EXPENSES FOR 2017 TO TOTAL IN RANGE OF $95-$100 MILLION

Jan 09 2018

Competitors

  Price Chg
Novartis AG (NOVN.S) CHF75.60 +0.10
Auris Medical Holding AG (EARS.OQ) $0.79 -0.05

Earnings vs. Estimates